A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting where good ideas are being implemented, it encourages their wider uptake.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Overall ranking Vacancies Funding Methodology Key Finding
  • Publications
  • The Lancet: Can the Antimicrobial Resistance...
Publication - published on 12 Oct 2017

The Lancet: Can the Antimicrobial Resistance Benchmark blaze a new trail?

A new Commentary, co-authored by Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, and Marc Mendelson, Professor of Infectious Diseases and Head of the Division of Infectious Diseases & HIV Medicine, University of Cape Town, published in The Lancet, discusses the potential of the new Antimicrobial Resistance Benchmark to stimulate pharmaceutical companies to limit antimicrobial resistance.

The Antimicrobial Resistance Benchmark is the first independently developed framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance (AMR). It was developed through consultation with stakeholders and experts working in AMR to build consensus on the priorities for pharmaceutical companies in AMR. 


Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.